IRWD

Over the past six months, Ironwood Pharmaceuticals experienced several stock-impacting events: the FDA approved LINZESS for pediatric patients aged 2 and older with functional constipation in May 2026, following priority review acceptance in January 2026 for ages 2 to 5 years. The company reported Q2 2026 results in August 2026, with EPS of $0.31 and revenue of $113.0 million, slightly missing analyst expectations, but subsequently raised its full-year 2026 financial guidance for LINZESS U.S. net sales to $1.15 - $1.20 billion and total revenue to $460 - $485 million. Strong Q1 2026 results were reported in May 2026, showing 97% year-over-year LINZESS U.S. net sales growth, and the company achieved its 2025 financial guidance while reiterating a strong 2026 outlook in February 2026. In June 2026, Ironwood repaid $200 million in convertible senior notes using cash on hand. The confirmatory Phase 3 STARS-2 trial for apraglutide in SBS-IF initiated in June 2026, though apraglutide's launch was delayed until 2029 due to an FDA request for an additional study. Leadership changes included the resignation of CFO Gregory Martini in May 2026 and the appointment of Dr. Jeffrey Silber as CMO and Head of R&D in July 2026. Analyst ratings varied, with Wall Street Zen and Zacks Research downgrading the stock, while Weiss Ratings upgraded it. Insider sales were also reported. The stock price saw a significant 189.73% increase between September 2025 and September 2026, with fluctuations between a 52-week high of $5.78 and a low of $1.26 as of September 2026.